Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…
Coverage & Reimbursement Challenges: Updates from the ACR Insurance Subcommittee Chair
The ACR Insurance Subcommittee is working to address specialty pharmacy requirements for in-office treatments, elimination of consultation codes and other coverage and reimbursement challenges.
Are Your Patients at Risk? Advocacy Matters
When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. You can make a difference.
Evaluation & Management Code Changes Set for 2021
Major changes to office and outpatient evaluation and management codes 99201–99205 and 99211–99215 will take effect Jan. 1, 2021.
Washington Legislature Introduces Student Loan Forgiveness Bill
A bill introduced in January in the Washington Legislature would allow pediatric and juvenile rheumatologists to access the state’s loan forgiveness program.
According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA
NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….
Even with Insurance, Fewer Americans Seeing Primary Care Providers
(Reuters Health)—Almost half of U.S. adults with private health insurance are not visiting primary care providers for routine care or sick visits, a new study suggests. Between 2008 and 2016, the number of annual primary care visits for every 100 people with private health insurance declined by 22%, from 169.5 to 134.3, the study found….
Varicella Zoster Virus Not Associated with Giant Cell Arteritis Pathogenesis
Researchers suggest antiviral therapy is not appropriate for patients with GCA, based on their study findings and related research…
Update on the Management of Takayasu Arteritis
A rare form of large vessel vasculitis, Takayasu arteritis persents with no clear patterns, with patients experiencing vascular symptoms, as well as such systemic symptoms as fever and weight loss. A systematic literature review found evidence to guide rheumatologists in monitoring and treating their patients with Takayasu arteritis…
Biologic Spending & Price Trends
Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…
- « Previous Page
- 1
- …
- 97
- 98
- 99
- 100
- 101
- …
- 317
- Next Page »